How This Evidence Evolved
Mechanical vs Bioprosthetic Heart Valves
Balancing Durability Against Anticoagulation Risk in Prosthetic Valve Selection
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
All-cause mortality at 15 years — mechanical AVR 66% vs bioprosthetic 79% (p=0.02); primary valve failure <65y: bio 26% vs mech 0% (p<0.001)
Survival at 20 years: Bjork-Shiley 25.0% vs porcine 22.6% (log rank p=0.39); major bleeding 40.7% vs 27.9% (p=0.008)
Follow-up studies, subgroup analyses, and real-world validation
Current standard of care and ongoing research directions
Landmark Trials in This Story
A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease
11-year mortality probability: mechanical 0.57 vs bioprosthetic 0.62 (P=.57); structural failure only in bioprostheses
Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial
All-cause mortality at 15 years — mechanical AVR 66% vs bioprosthetic 79% (p=0.02); primary valve failure <65y: bio 26% vs mech 0% (p<0.001)
Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.
Survival at 20 years: Bjork-Shiley 25.0% vs porcine 22.6% (log rank p=0.39); major bleeding 40.7% vs 27.9% (p=0.008)
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
Valve thrombosis or thromboembolism: apixaban 4.2% vs warfarin 1.3% per patient-year (difference 2.9, 95% CI 0.8-5.0); noninferiority not met
Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement.
15-year mortality after AVR at age 45-54: biologic 30.6% vs mechanical 26.4% (HR 1.23, 95% CI 1.02-1.48, P=0.03)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.